|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Theragene Pharmaceuticals, Inc.
0 Patents (Medical) associated with Theragene Pharmaceuticals, Inc.
20 May 2014·Journal of Clinical Oncology
Characterization of the mTOR autophosphorylation site, S2481, as a novel biomarker in renal cell carcinoma (RCC).
Author: Brooks, James D. ; Harshman, Lauren Christine ; Berglin, Jon ; Hunter, Tony ; Muller, Karra ; Copp, Jeremy ; Lin, Chii-Dean ; Higgins, John
4571 Background: mTOR inhibitors have clinical utility in VEGF-refractory RCC and may be useful in non-clear cell disease. In general, mTOR inhibition is inferior to targeting VEGF in the treatment...
100 Deals associated with Theragene Pharmaceuticals, Inc.
100 Translational Medicine associated with Theragene Pharmaceuticals, Inc.